No Data
No Data
Sinopharm Reports Steady Mid-Year Financial Growth
Sinopharm (01099): The net income attributable to the parent of China National Medicines Corporation (600511.SH) for the first half of the year was 1.001 billion yuan, a year-on-year increase of 1.62%.
Sinopharm (01099) released its subsidiary China National Medicines Corporation (Sinopharm) as of 2024...
Express News | Sinopharm Group - Hy Net Profit Attributable RMB1.00 Bln for China National Medicines Corp
SINOPHARM: ANNOUNCEMENTPRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD)FOR THE SIX MONTHS ENDED 30 JUNE 2024
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
China National Accord Medicines' H1 Profit Slips 11%, Revenue Down 2%; Shares Drop 4%
No Data